Summary of use during lactation
Although no published information is available on the use of cefepime during breastfeeding, the levels in breastmilk appear to be low and cephalosporins are generally not expected to cause serious adverse effects in breastfed infants. No human information is available on enmetazobactam (a component of Exblifep) in breastmilk, but its excretion is probably low like other beta-lactams. Occasionally disruption of the infant’s gastrointestinal flora, resulting in diarrhea or thrush, have been reported with cephalosporins, but these effects have not been adequately evaluated. Cefepime is acceptable in nursing mothers. The combination of cefepime and enmetazobactam has not been studied in humans during breasteeding, but the same adverse effects should apply.
Drug levels in milk and infant serum
Maternal Levels. The manufacturer reports that the concentration of cefepime in breastmilk is about 0.5 mcg/mL, following a single intravenous dose of 1 gram. This is consistent with the low levels of other cephalosporins in breastmilk. Infant Levels. Relevant published information was not found as of the revision date.
Effects in breastfed infants
Relevant published information was not found as of the revision date.
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
Alternative drugs to consider
Ceftazidime, Ceftriaxone
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.